Search research articles
Contact Us
Filters
Showing results (11-20 of 192) with videos related to
Page
of 20
Sort By:
Cancer Biology & Therapy
|
November 13, 2004
NF-kappaB, IL-6 and myeloma cell growth: making the connection
Mark Y Chiang, Edward A Stadtmauer
Blood Cancer Discovery
|
September 28, 2023
Understanding Infection Risk with Anti-BCMA Bispecific Antibodies
Alfred L Garfall, Edward A Stadtmauer
Drugs & Aging
|
August 17, 2002
High-dose chemotherapy and stem cell support for breast cancer: where are we now?
Renee M Gerrero, Steven Stein, Edward A Stadtmauer
The Annals of Pharmacotherapy
|
December 31, 2002
Concurrent administration of interferon alfa-2b and beta-1a
Tawee Tanvetyanon, Edward A Stadtmauer, Lawrence A Kerson
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
|
February 13, 2007
Medical management update: multiple myeloma
Eric T Stoopler, Dan T Vogl, Edward A Stadtmauer
The New England Journal of Medicine
|
January 14, 2016
Chimeric Antigen Receptor T Cells in Myeloma
Alfred L Garfall, Edward A Stadtmauer, Carl H June
Leukemia
|
March 30, 2022
CAR T cell therapy for multiple myeloma: What have we learned?
Sandra Susanibar Adaniya, Edward A Stadtmauer, Adam D Cohen
Cancer Journal (Sudbury, Mass.)
|
February 4, 2016
The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies
Sarah J Nagle, Alfred L Garfall, Edward A Stadtmauer
Transfusion
|
February 1, 2013
The evolving role of plerixafor in hematopoietic progenitor cell mobilization
Yvette C Tanhehco, Dan T Vogl, Edward A Stadtmauer, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 1, 2017
Hematologic Malignancies: Plasma Cell Disorders
Madhav V Dhodapkar, Ivan Borrello, Adam D Cohen, et al.
Page
of 20
Search research articles
Search
Showing results (11-20 of 192) with videos related to
Sort By:
Page
of 20
Cancer Biology & Therapy
|
November 13, 2004
NF-kappaB, IL-6 and myeloma cell growth: making the connection
Mark Y Chiang, Edward A Stadtmauer
Blood Cancer Discovery
|
September 28, 2023
Understanding Infection Risk with Anti-BCMA Bispecific Antibodies
Alfred L Garfall, Edward A Stadtmauer
Drugs & Aging
|
August 17, 2002
High-dose chemotherapy and stem cell support for breast cancer: where are we now?
Renee M Gerrero, Steven Stein, Edward A Stadtmauer
The Annals of Pharmacotherapy
|
December 31, 2002
Concurrent administration of interferon alfa-2b and beta-1a
Tawee Tanvetyanon, Edward A Stadtmauer, Lawrence A Kerson
Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics
|
February 13, 2007
Medical management update: multiple myeloma
Eric T Stoopler, Dan T Vogl, Edward A Stadtmauer
The New England Journal of Medicine
|
January 14, 2016
Chimeric Antigen Receptor T Cells in Myeloma
Alfred L Garfall, Edward A Stadtmauer, Carl H June
Leukemia
|
March 30, 2022
CAR T cell therapy for multiple myeloma: What have we learned?
Sandra Susanibar Adaniya, Edward A Stadtmauer, Adam D Cohen
Cancer Journal (Sudbury, Mass.)
|
February 4, 2016
The Promise of Chimeric Antigen Receptor Engineered T Cells in the Treatment of Hematologic Malignancies
Sarah J Nagle, Alfred L Garfall, Edward A Stadtmauer
Transfusion
|
February 1, 2013
The evolving role of plerixafor in hematopoietic progenitor cell mobilization
Yvette C Tanhehco, Dan T Vogl, Edward A Stadtmauer, et al.
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting
|
June 1, 2017
Hematologic Malignancies: Plasma Cell Disorders
Madhav V Dhodapkar, Ivan Borrello, Adam D Cohen, et al.
Page
of 20